Psoriatic Arthritis
From the Journals
Study of biologics’ impact on psoriasis-to-PsA transition contradicts previous findings
Differing patient selection criteria and other biases may be why results from a large EHR administrative database study contradict those from...
Conference Coverage
First-in-class TYK inhibitor shows durable effect for psoriasis
“Deucravacitinib is very distinct from the other JAK inhibitors, and I think we are seeing this in the clinical studies.”
Feature
Acceptance of biosimilars grows but greater use may hinge on switching, interchangeability studies
The slow adoption of biosimilars in the United States has begun to pick up and experts hope that they can put a brake on drug spending, but...
From the Journals
More severe psoriasis linked to an increased risk of PsA
“Timely and accurate diagnosis of PsA is important for improved patient outcomes and appropriate disease management and may prevent prolonged...
Latest News
European agency recommends two new adalimumab biosimilars
The Committee for Medicinal Products for Human Use gave a positive opinion for the approval of Hukyndra and Libmyris, each of which will have 15...
From the Journals
Medicare patients’ cost burden for specialty psoriasis, PsA drugs remains high
Coverage of and access to biologics for psoriasis and psoriatic arthritis are compromised by out-of-pocket payments and prior authorization...
From the Journals
Cannabidiol found no better than placebo for hand arthritis pain
Patients with hand osteoarthritis or psoriatic arthritis who used cannabidiol as an add-on analgesic had results similar to those of placebo.
News from the FDA/CDC
Three JAK inhibitors get boxed warnings, modified indications
The FDA is limiting all approved uses of tofacitinib, baricitinib, and upadacitinib to patients who have not responded well to TNF blockers, to...
From the Journals
Biologic benefit in psoriasis might extend to arthritis prevention
People with psoriasis had a lower risk for psoriatic arthritis if they had been treated with a biologic than if they had not, based on a study of...
News
Bimekizumab approved in Europe for psoriasis treatment
In the United States, the Food and Drug Administration is expected to make a decision on approval of bimekizumab for treating psoriasis on Oct. 15...
Conference Coverage
Psoriatic arthritis health care costs continue to rise over time
In a database claims review, the average person with PsA had higher inpatient, outpatient, and pharmacy costs, compared with those with only...